Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...

According to Benzinga Pro, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 10.61%, which means the company has more short interest than most of its peers. Did ...

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Halozyme (HALO – Research Report), with a ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $57.15 which represents a slight increase of $6.58 or 13.01% from the prior close of $50.57. The stock opened ...

Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.

Halozyme Therapeutics ( (HALO) ) has released its Q3 earnings. Here is a breakdown of the information Halozyme Therapeutics presented to its ...

As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...

Halozyme Therapeutics Inc (HALO) reports a 34% revenue increase, raises full-year guidance, and expands partnerships despite ...

Shares of Halozyme Therapeutics rose after the company reported earnings growth in the latest quarter and raised its outlook for the year. The stock was up 11% to $56.25 in post-market trading.